Avalon Ventures Gets Exit At Sitari Pharmaceuticals
socalTECH
SEPTEMBER 11, 2019
San Diego-based biotech investor Avalon Ventures has scored an exit, saying late Tuesday evening that it has entered into a definitive agreement with GlaxoSmithKline (GSK), to sell Sitari Pharmaceuticals to GSK. who also serves as President and CEO of COI and is a Managing Director at Avalon Ventures.
Let's personalize your content